Table 4.
Association Between ABCD-GENE Score and Major Atherothrombotic Events with CYP2C19 Intermediate Metabolizers (IMs) and non-IMs within 1-Year After Percutaneous Coronary Intervention
| No. of events | Event rate per 100 person-years | Unadjusted HR | Adjusted HRa | |
|---|---|---|---|---|
| Major atherothrombotic events | ||||
| ABCD-GENE score ≥10 (n=505) |
62 | 24.6 (95% CI, 18.5 – 30.8) |
Reference | Reference |
| ABCD-GENE score <10: IMs (n=159) |
16 | 20.1 (95% CI, 10.3 – 30.0) |
0.82 (95% CI, 0.47–1.42) P=0.482 |
1.03 (95% CI, 0.59–1.81) P=0.917 |
| ABCD-GENE score <10: Non-IMs (n=1677) |
134 | 14.2 (95% CI, 11.8 – 16.6) |
0.60 (95% CI, 0.44–0.81) P<0.001 |
0.58 (95% CI, 0.43–0.79) P<0.001 |
| MACE | ||||
| ABCD-GENE score ≥10 (n=505) |
42 | 16.7 (95% CI, 11.6 – 21.7) |
Reference | Reference |
| ABCD-GENE score <10: IMs (n=159) |
10 | 12.6 (95% CI, 4.8 – 20.4) |
0.76 (95% CI, 0.38–1.51) P=0.431 |
0.97 (95% CI, 0.48–1.95) P=0.925 |
| ABCD-GENE score <10: Non-IMs (n=1677) |
93 | 9.9 (95% CI, 7.9 – 11.9) |
0.61 (95% CI, 0.43–0.88) P=0.009 |
0.61 (95% CI, 0.42–0.88) P=0.008 |
Model adjusted for: sex, smoking status, percutaneous coronary intervention (PCI) indication (i.e., MI vs. UA or elective PCI), PCI strategy (i.e., stent versus percutaneous transluminal coronary angioplasty), and institution
ABCD-GENE (Age, oBesity, Chronic kidney disease, Diabetes, CYP2C19 GENEtic variants); IM: CYP2C19 intermediate metabolizer; MACE, major adverse cardiovascular events. Non-CYP2C19 IMs consists of CYP2C19: normal, rapid, and ultra-rapid metabolizers. Major atherothrombotic events defined as the composite of death, myocardial infarction (MI), ischemic stroke, stent thrombosis (ST), or unstable angina (UA) requiring revascularization. MACE defined as the composite of cardiovascular death, MI, ST, or ischemic stroke.